Adaptive develops disease-modifying, multi-system technologies for Parkinson’s disease and other systemic degenerative conditions.

Our lead technology, ABS-11101, is currently in late development, with trials to begin in 2026. Enrollment has not yet begun. For more information, please contact adaptive@adaptivebiosciences.com.